Drug Discovery · New Haven, CT · Founded 2019 · Publicly Held
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. VeraDermics (NYS: MANE) is based in New Haven, CT and was founded in 2019. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $596 million (Feb 2026). It has raised $519 million across 1 recorded round; the latest was a $150 million Series C in Oct 2025.
Last price · $/share
—
Implied valuation
$596.3M
Total raised
$518.6M
Last round
Later Stage VC (Series C)
Oct 2025
No prints on record
No secondary trades in VeraDermics (NYS: MANE) shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of VeraDermics (NYS: MANE) stock.
